Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 5/20 | 0.53 |
| ▸ | LGALS9 | O00182 | 4/20 | 0.53 |
| ▸ | LGALS1 | P09382 | 4/20 | 0.53 |
| ▸ | LGALS7; LGALS7B | P47929 | 3/20 | 0.53 |
| ▸ | SELP | P16109 | 7/20 | 0.46 |
| ▸ | SELE | P16581 | 1/20 | 0.45 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | PDIA4 | P13667 | 1/20 | 0.41 |
| ▸ | PDIA3 | P30101 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826299 | 1.00 | LGALS3 (0.53) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL7799368 | 1.00 | LGALS3 (0.53) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL15815859 | 0.92 | LGALS3 (0.58) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL17318202 | 0.92 | LGALS3 (0.58) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL4954660 | 0.92 | LGALS3 (0.58) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL4534423 | 0.92 | LGALS3 (0.58) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL7221498 | 0.92 | LGALS3 (0.58) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL14530940 | 0.90 | LGALS3 (0.56) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL2506760 | 0.90 | LGALS3 (0.56) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP | |
| SCHEMBL2508264 | 0.90 | LGALS3 (0.56) | LGALS3LGALS9LGALS1LGALS7; LGALS7BSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010011075-A1 | 5'-SUBSTITUTED-RIBOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | TOWNSEND LEROY B (US) | 2001-08-02 | — | — | US | disclosed |
| US-5874413-A | CYTOMEGALO VIRUS | UNIVERSITY OF MICHIGAN (US) | 1999-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011075-A1 | 5'-SUBSTITUTED-RIBOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, IFNAR1 | LGALS3 1980/4885LGALS9 3743/4885LGALS1 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.